Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been assigned an average recommendation of "Buy" from the seven research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $20.20.
A number of research analysts recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Altimmune in a report on Thursday, April 3rd. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Finally, Wall Street Zen raised Altimmune from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd.
View Our Latest Stock Report on Altimmune
Insider Activity at Altimmune
In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of the stock in a transaction on Thursday, March 13th. The stock was acquired at an average price of $5.20 per share, with a total value of $52,000.00. Following the completion of the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 4.10% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Altimmune
Several institutional investors have recently added to or reduced their stakes in ALT. Ameriprise Financial Inc. boosted its holdings in Altimmune by 35.6% in the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after acquiring an additional 1,378,854 shares in the last quarter. RFG Advisory LLC acquired a new stake in Altimmune in the first quarter worth about $1,622,000. Nuveen LLC acquired a new stake in Altimmune in the first quarter worth about $1,304,000. Invesco Ltd. lifted its holdings in shares of Altimmune by 679.2% during the fourth quarter. Invesco Ltd. now owns 247,086 shares of the company's stock worth $1,781,000 after purchasing an additional 215,375 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Altimmune by 139.8% during the fourth quarter. Millennium Management LLC now owns 345,637 shares of the company's stock worth $2,492,000 after purchasing an additional 201,484 shares during the period. Institutional investors and hedge funds own 78.05% of the company's stock.
Altimmune Price Performance
Shares of ALT stock traded up $0.33 during trading hours on Friday, reaching $5.95. 2,705,962 shares of the company traded hands, compared to its average volume of 2,830,968. Altimmune has a 12-month low of $3.55 and a 12-month high of $11.16. The company has a market cap of $482.59 million, a P/E ratio of -3.84 and a beta of 0.58. The firm has a 50-day moving average price of $5.13 and a 200 day moving average price of $6.31.
Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. During the same period in the previous year, the firm earned ($0.34) EPS. Sell-side analysts predict that Altimmune will post -1.35 EPS for the current year.
Altimmune Company Profile
(
Get Free ReportAltimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Featured Stories

Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.